Le Lézard
Classified in: Health
Subject: MIN

MOVEMBER TO INVEST UP TO $5.8 MILLION CAD INTO PROSTATE CANCER RESEARCH PROJECTS ACROSS CANADA


Canadian researchers and organizations can apply for new grant initiatives aimed at tackling gaps in prostate cancer treatment and care.

TORONTO, Sept. 21, 2023 /CNW/ - Movember, the world's leading global men's health charity, will be investing a total of up to $5.8 million CAD in funding for researchers and/or organizations across Canada that qualify for one of four new global research grant programs, each aimed at reducing the numbers of men dying from prostate cancer and improve quality of life for those living with the disease.

Globally, prostate cancer is the most common cancer in men over 45. Every year, more than 1.4 million men are diagnosed with prostate cancer worldwide, with 375,000 lost to the disease. In Canada, one in eight men will be diagnosed with prostate cancer in their lifetime, making it the most commonly diagnosed cancer in Canadian men overall.

Over the last 20 years, Movember has led the way in prostate cancer research, bringing together the best minds from around the world and supporting the development of life-extending therapies and more accurate diagnostic tests. Through fundraising efforts, Movember has invested almost $314M CAD in over 600 biomedical research projects and close to $190M CAD in clinical quality and survivorship projects globally. This newest round of global grant initiatives aims to bring together teams of experts from around the world to tackle some of the biggest challenges in the treatment and care of men with prostate cancer.

In Canada, Movember is the largest funder of research focused on translating laboratory findings into new prostate cancer treatment options and the second largest funder of overall projects relating to prostate cancer research, having invested over $107 million CAD since 2008.

But despite considerable advances in treatment and care, prostate cancer remains the second highest cause of cancer-related deaths in men worldwidei. Too many men with prostate cancer have poor physical and mental health ? often because of their treatment or a healthcare system that fails to support their needs.

"At Movember, we are driven by impact. Prostate Cancer remains the number one priority issue with our community in Canada," says Todd Minerson, Movember Canada Country Director.  "We spent a year listening to and consulting with our community of researchers, clinicians, healthcare professionals and those with lived experience of prostate cancer to identify the greatest priorities for research and gaps within treatment and careThese new grant opportunities were identified to provide significant impact in Canada and around the world."

As a result of this process, Movember is announcing four new prostate cancer research programs, with a Canadian funding investment of $5.8M CAD, aimed at reducing the number of men whose disease becomes incurable and delivering more consistent and improved personalized care to reduce variation in prostate cancer treatment and outcomes.

NEW INVESTMENTS INCLUDE:

Preventing Disease Progression in Prostate Cancer Program ? up to $1.5M CAD

Personalized Active Surveillance Program - up to $750K CAD

Health Equity Grants Initiative - $2.1M CAD

The Patient-Reported Outcome Measures (PROMS) Program - $1.5M CAD

Organizations and researchers interested in submitting for one of the grants can find more information on current funding opportunities at https://ca.movember.com/about/funding.

About Movember

Movember is the leading charity changing the face of men's health on a global scale. Since 2003, the men's health movement has funded vital men's health projects, challenged the status quo, shaken up men's health research and transformed the way health services reach and support men. Taking on mental health and suicide prevention, prostate cancer, and testicular cancer with unwavering determination. Supporting men to live healthier, longer lives.  Movember are working with community and expert partners year-round to improve the health of men and boys, their families, mates, and communities. The charity's vision is to have an everlasting impact on the face of men's health. Leading the charge in encouraging men to adopt healthy behaviours, challenging health systems and confronting gender norms to reduce health inequalities and save more lives.

____________________________________

i Data Source: International Agency for Research on Cancer (IARC), Date Accessed: 2022-08-03, Dataset Name: International Agency for Research on Cancer (IARC).

SOURCE Movember Canada


These press releases may also interest you

at 07:45
Agenus Inc. ("Agenus") , a leader in discovering and developing novel immunological agents to treat various cancers, today announced results for the first quarter 2024. In a concurrent press release accompanying Agenus' earnings announcement, a $100M...

at 07:40
One year since forming its Advisory Board, Lokavant, the clinical trial intelligence platform company, announces three new members, including Pfizer's Head of Predictive Analytics Jonathan Crowther. The Lokavant Advisory Board brings together...

at 07:39
Lucid Diagnostics Inc.  ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc....

at 07:35
Ligand Pharmaceuticals Incorporated and Agenus Inc. , a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus'...

at 07:35
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference...

at 07:30
Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus...



News published on and distributed by: